AIM Immunotech Inc. — FY2020 Form 10-K
Business context and period. This annual report covers the year ended December 31, 2020, not a standalone fourth quarter. AIM is a clinical-stage immunopharmaceutical company developing Ampligen (rintatolimod) for cancer, ME/CFS and viral indications, including COVID-19. Alferon N Injection is approved in the U.S. for certain genital warts, but commercial sales were halted pending manufacturing and FDA release steps. Ampligen was not FDA-approved or marketed in the U.S.; its Argentine commercial launch remained pending final inspection and release testing.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $163,000 | $140,000 |
| Operating loss | $15.152 million | $12.443 million |
| Net loss | $14.400 million | $9.404 million |
| Basic and diluted loss per share | $0.45 | $2.58 |
| Cash used in operating activities | $10.368 million | $9.067 million |
| Cash used in investing activities | $9.164 million | $6.147 million |
| Cash provided by financing activities | $56.563 million | $16.385 million |
Revenue consisted of Ampligen cost-recovery clinical treatment programs; AIM reported no Alferon finished goods available for commercial sale. Revenue rose about 16%, while the net loss widened about 53%. R&D expense increased 23% to $5.720 million and G&A increased 23% to $8.654 million. The filing does not report a meaningful commercial gross margin.
At year-end, cash and cash equivalents were $38.501 million and marketable securities totaled $15.877 million, for combined liquidity of approximately $54.378 million. Total assets were $64.584 million and stockholders’ equity was $61.294 million. Notes payable were zero at year-end; liabilities included a $2.106 million financing obligation from the sale-leaseback transaction and $180,000 of redeemable warrants. Management estimated funds would support anticipated operating needs and current clinical trials for approximately 24 months, while warning that further financing could be needed.
Material changes and unusual items
- Net loss increased primarily due to higher R&D and G&A, a $1.633 million adverse year-over-year swing in warrant revaluation, and the absence of a $1.217 million insurance settlement gain recorded in 2019. These were partly offset by debt-extinguishment gains in 2020 and higher NOL-sale proceeds.
- AIM recorded a $1.095 million write-off of Alferon work-in-process inventory in R&D expense because production was delayed beyond the inventory’s usable period. It also recorded a $135,000 impairment of a supplier deposit.
- Financing generated $61.248 million net from stock issuance. The company sold 20.4 million shares through its Maxim equity distribution agreement during 2020. Common shares outstanding rose from 10.387 million at year-end 2019 to 42.154 million at year-end 2020. The filing reports 47.822 million shares outstanding as of March 26, 2021; it also reports 5.656 million additional ATM shares sold after year-end and termination of that agreement in February 2021.
- In December 2020, the company sold $10 million of New Jersey state net operating losses for approximately $1.090 million. The reported gain from sale of tax operating losses was $1.186 million, including a deferred tax benefit.
- The filing identifies an immaterial revision of previously reported tax-related amounts, including a $535,000 deferred-tax-related error and adjustments to prior-period accumulated deficit and loss. It also reports accumulated deficit as approximately $342.605 million in one risk-factor passage, versus $341.974 million on the year-end balance sheet; the filing text does not provide a clear reconciliation.
Outlook, commentary and principal risks
- Management said it did not expect material operating revenue in the near term. It cited the need for additional funding if studies require expansion or unanticipated work, or if commercialization and partnering do not progress.
- Ampligen’s FDA application for CFS received a Complete Response Letter in 2013. The FDA cited insufficient evidence of efficacy and safety-data limitations and requested additional work; U.S. approval remains uncertain. Argentine approval is not final authorization to sell: inspection and product release steps remained outstanding and were delayed.
- AIM reported a positive survival result in a 42-patient pancreatic-cancer Early Access Program compared with matched historical controls. This is not a randomized controlled result. The company planned to seek FDA fast-track and possibly breakthrough designation and pursue a follow-up Phase 2/3 study.
- COVID-19 work remained investigational. A Roswell Park Phase 1/2a study of Ampligen plus interferon in cancer patients with COVID-19 had enrolled and treated its first patient in November 2020. The company also described preclinical findings and planned an intranasal Phase 1 study; a subsequent-events disclosure says that study was expected to cost approximately $980,000. No human efficacy for COVID-19 was established in the filing.
- Clinical progress and commercialization face pandemic-related delays, regulatory and manufacturing hurdles, limited suppliers, reliance on collaborators and contract manufacturers, and competition from better-resourced companies. Alferon production was on hold with no definitive restart timetable; the company estimated approximately $10 million would be needed to restart manufacturing.
- Other risks include substantial historical losses, potential future dilution, volatile share price, uncertain reimbursement, product-liability exposure and pending legal matters. The company disclosed a BioLife contract dispute and a contested £110,250 claim from Symbiosis; no outcome was determined.
Most important facts for investors to verify
- Cash, marketable securities, cash burn and the basis for management’s approximately 24-month runway estimate.
- Share-count changes, post-year-end ATM issuance, remaining warrants and options, and potential dilution.
- Regulatory and release-testing milestones for Ampligen’s Argentina launch, and the status and requirements of its FDA CFS application.
- Whether pancreatic-cancer findings are replicated in controlled clinical trials, and whether planned COVID-19 and oncology trials proceed with funding and enrollment.
- Manufacturing restart costs, Alferon inventory and facility inspection requirements, and Ampligen supply capacity and vendor arrangements.
- The tax-related prior-period revision and the differing accumulated-deficit figures stated in the filing.